To further confirm that KREMEN2 is a determinant of synthetic lethality through simultaneous inhibition of CBP/p300 in SMARCA4/SMARCA2-deficient cells and SS18–SSX fusion cancer cells, we investigated whether depleting KREMEN2 affects cell viability. Here, EP300 is linked to cancer.